Skip to Content, Navigation, or Footer.
The Tufts Daily
Where you read it first | Tuesday, April 23, 2024

Alex Viveros


The Setonian
News

The Daily's COVID-19 dashboard

Positive cases and isolation numbers have seen a slight rise since last week. The Medford/Somerville campus reported 19 new cases on Friday. The seven-day trailing average number of new cases on the Medford/Somerville campus was 19.29 on Feb. 11, up from 17.57 the week before.

9212325177_6f1fdaa880_o
Science

This Week in Science: Moderna boosters approved, koala chlamydia vaccine trial starts, NASA launches spaceship, leading primate center to be shut down

An FDA advisory panelunanimously voted last week to approve the use of a booster shot for the Moderna vaccine and again voted unanimously yesterday to approve a booster for the Johnson & Johnson vaccine. Moderna’s booster only applies to certain groups of people, such as those over the age of 65, high-risk individuals between the ages of 18 and 64 or people whose jobs put them at risk of contracting COVID-19. The individuals in all three categories should wait at least six months after their second dose to receive their Moderna booster shot. Although the FDA panel unanimously decided to approve the booster for those categories, the panel did not make any decisions on whether to recommend booster shots for low-risk adults over 18. Some members believe it is too early to make the call; they argue that as more people become eligible for the booster, it will be crucial to determine if it is effective at providing better protection against COVID-19. Additionally, some scientists say that there is not enough evidence to suggest that vaccine efficacy is decreasing, which, if true, could make a booster shot pointless.

9187712502_bbecd929e1_b
Science

This week in Science: FDA okays e-cig, first malaria vaccine approved, toilet bats discovered

The U.S. Food and Drug Administrationgranted market authorization to an electronic cigarette company for the first time on Tuesday, approving certain products for sale in the United States. The FDAapproved three products from R.J. Reynolds Vapor Company’s brand, Vuse, in an effort to diminish the impacts of traditional cigarettes, whose carcinogenic properties contribute to an estimated 400,000 U.S. deaths each year. The FDA concluded that the reduced morbidity and mortality among smokers outweigh the risks that approving Vuse products poses to youth. Notably, 10% of high school students who use e-cigarettes said Vuse is their usual brand.

More articles »